Defining the specificity and function of a human neutralizing antibody for Hepatitis B virus

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Hepatitis B Virus (HBV) is a major cause of viral liver disease globally.
• Understanding natural human immunity to HBV is crucial for developing effective treatments.

Purpose of the Study:

• To isolate and characterize a fully human monoclonal antibody (HuMab) with potent anti-HBV activity.
• To evaluate the therapeutic and prophylactic potential of this HuMab in vivo.

Main Methods:

• Isolation of HuMab from memory B cells of an HBV-infected patient.
• Biochemical, biophysical, and functional characterization of antibody binding and neutralization against HBV genotypes.
• In vivo efficacy studies using human liver chimeric mouse models.

Main Results:

• Successful isolation and characterization of a lead HuMab candidate with strong binding and neutralizing activity against live HBV.
• Detailed analysis confirmed specificity and affinity across principal HBV genotypes.
• Demonstrated in vivo prophylactic and therapeutic potential in a relevant animal model.

Conclusions:

• The identified HuMab represents a promising new antibody-based therapeutic candidate for Hepatitis B Virus infection.
• These findings enhance the understanding of natural human immune responses to HBV.
• The antibody holds potential for both prophylaxis and therapy against HBV.